← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-11 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
CGTBiologicstaleShenzhen Geno-Immune Medical In…Phase 1

prophylactic 4SCAR19 cells (prophylactic 4SCAR19 cells)

B Acute Lymphoblastic Leukemia · B Acute Lymphoblastic Leukemia

#BAcuteLymphoblasticLeukemia#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
AntibodystaleTianjin Medical University Canc…Phase 2

trastuzumab (Herceptin, pyrotinib + trastuzumab + nab-paclitaxel)

HER2+ Early or Locally Advanced Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy)

HER2-positive Breast Cancer; Neoadjuvant Therapy · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleJiangsu Hengrui Pharmaceutical …Phase 2

trastuzumab (Herceptin, pyrotinib combined with trastuzumab, dalpiciclib and letrozole)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
CGTBiologicstaleMyrtelle Inc.Phase 2

rAAV-Olig001-ASPA (rAAV-Olig001-ASPA)

Canavan Disease · Canavan Disease

#CanavanDisease#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleSTZ eyetrialPhase 2

rAAV.hCNGA3 (rAAV.hCNGA3)

Achromatopsia · Achromatopsia

#Achromatopsia#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstaleLions Eye Institute, Perth, Wes…Phase 2

rAAV.sFlt-1 (rAAV.sFlt-1)

Macular Degeneration; Age-related Maculopathies · Macular Degeneration

#MacularDegeneration#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleNationwide Children's HospitalPhase 1

rAAV1.tMCK.human-alpha-sarcoglycan- First cohort (rAAV1.tMCK.human-alpha-sarcoglycan- First cohort)

Muscular Dystrophies · Muscular Dystrophies

#MuscularDystrophies#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleUniversity of Massachusetts, Wo…Phase 1

rAAV2-CB-hAAT Gene Vector (rAAV2-CB-hAAT Gene Vector)

Alpha 1-Antitrypsin Deficiency · Alpha 1-Antitrypsin Deficiency

#Alpha1-AntitrypsinDeficiency#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleBeacon TherapeuticsPhase 2

rAAV2-CB-hRPE65 (rAAV2-CB-hRPE65)

Leber Congenital Amaurosis · Leber Congenital Amaurosis

#LeberCongenitalAmaurosis#CGT#Phase2#세포유전치료#CAR-T+2
효능 ORR 2%임상시험 1상태 ACTIVE
CGTBiologicstaleUniversity of PennsylvaniaPhase 1

rAAV2-CBSB-hRPE65 (rAAV2-CBSB-hRPE65)

Amaurosis of Leber; Retinal Diseases · Amaurosis of Leber

#AmaurosisofLeber#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleNationwide Children's HospitalPhase 1

d3990 (rAAV2.5-CMV-minidystrophin, rAAV2.5-CMV-minidystrophin (d3990))

Duchenne Muscular Dystrophy · Duchenne Muscular Dystrophy

#DuchenneMuscularDystrophy#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleUniversity of OxfordPhase 2

rAAV2.REP1 (rAAV2.REP1)

Choroideremia · Choroideremia

#Choroideremia#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleUniversity of AlbertaPhase 2

rAAV2.REP1 vector (rAAV2.REP1 vector)

Choroideremia · Choroideremia

#Choroideremia#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleNantes University HospitalPhase 2

rAAV2/4.hRPE65 (rAAV2/4.hRPE65)

Leber Congenital Amaurosis · Leber Congenital Amaurosis

#LeberCongenitalAmaurosis#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleDigna Biotech S.L.Phase 1

rAAV2/5-PBGD vector dosage 1 (rAAV2/5-PBGD vector dosage 1)

Acute Intermittent Porphyria · Acute Intermittent Porphyria

#AcuteIntermittentPorphyria#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleDigna Biotech S.L.Phase 1

rAAV2/5-PBGD vector dosage 2 (rAAV2/5-PBGD vector dosage 2)

Acute Intermittent Porphyria · Acute Intermittent Porphyria

#AcuteIntermittentPorphyria#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleDigna Biotech S.L.Phase 1

rAAV2/5-PBGD vector dosage 3 (rAAV2/5-PBGD vector dosage 3)

Acute Intermittent Porphyria · Acute Intermittent Porphyria

#AcuteIntermittentPorphyria#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleDigna Biotech S.L.Phase 1

rAAV2/5-PBGD vector dosage 4 (rAAV2/5-PBGD vector dosage 4)

Acute Intermittent Porphyria · Acute Intermittent Porphyria

#AcuteIntermittentPorphyria#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleBeacon TherapeuticsPhase 2

rAAV2tYF-CB-hRS1 (rAAV2tYF-CB-hRS1)

X-linked Retinoschisis · X-linked Retinoschisis

#X-linkedRetinoschisis#CGT#Phase2#세포유전치료#CAR-T+2
효능 ORR 39.5%임상시험 1상태 ACTIVE

174 / 177 페이지

← 이전다음 →